Press release
Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025
A Deadline is coming up on April 14, 2025 in the lawsuit for certain investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA).
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and there are strict and short deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the District of Massachusetts the plaintiff alleges on behalf of purchasers of Intellia Therapeutics, Inc. (NASDAQ: NTLA) common shares between July 30, 2024 to January 8, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between July 30, 2024 to January 8, 2025, the defendants made false and/or misleading statements and/or failed to disclose that the defendants created the false impression that they possessed reliable information pertaining to the viability of NTLA-3001's development and eventual marketing, if approved, that Intellia's optimistic reports of timelines, including dosing and future studies of the drug, fell short of reality; the NTLA program was not viable or sustainable for Intellia because viral-based editing programs remained expensive and inefficient in comparison to then-existing non-viral delivery methods, that Intellia was not equipped to timely dose patients with NTLA-3001, maintain the drug's research and development, or even to maintain its full staff in light of the existing scientific landscape surrounding viral-based editing drugs, and that even if NTLA-3001 proved successful, the use of viral-based editing drugs is costly, inefficient, and poor mitigators of adverse effects in patients.
Those who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Intellia Therapeutics, Inc. (NASDAQ: NTLA) Investor Alert: Deadline in Lawsuit on April 14, 2025 here
News-ID: 3961555 • Views: …
More Releases from Shareholders Foundation, Inc.
Lawsuit Notice: Investors who lost money with Alexandria Real Estate Equities, I …
An investor, who purchased shares of Alexandria Real Estate Equities, Inc. (NYSE: ARE), filed a lawsuit over alleged violations of Federal Securities Laws by Alexandria Real Estate Equities, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Alexandria Real Estate Equities, Inc. (NYSE: ARE) have certain options and for certain investors are short and strict deadlines running. Deadline: January 26, 2026. NYSE: ARE investors should…
Lawsuit filed for Investors who lost money withs shares of StubHub Holdings, Inc …
An investor, who purchased shares of StubHub Holdings, Inc. (NYSE: STUB), filed a lawsuit over alleged violations of Federal Securities Laws by StubHub Holdings, Inc. in connection with certain allegedly false and misleading statements made connection with StubHub's September 17, 2025 initial public offering (the "IPO").
Investors who purchased shares of StubHub Holdings, Inc. (NYSE: STUB) have certain options and for certain investors are short and strict deadlines running. Deadline:…
Jayud Global Logistics Limited (NASDAQ: JYD) Investor Alert: Lawsuit alleges Mis …
An investor, who purchased shares of Jayud Global Logistics Limited (NASDAQ: JYD), filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Jayud Global Logistics Limited in connection with certain allegedly false and misleading statements made between April 21, 2023 and April 30, 2025.
Investors who purchased shares of Jayud Global Logistics Limited (NASDAQ: JYD) have certain options and for certain investors are short and strict deadlines…
Lawsuit Alert: Investors who lost money with shares of Skye Bioscience, Inc. (NA …
An investor, who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE), filed a lawsuit over alleged violations of Federal Securities Laws by Skye Bioscience, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Skye Bioscience, Inc. (NASDAQ: SKYE) have certain options and for certain investors are short and strict deadlines running. Deadline: January 16, 2026. NASDAQ: SKYE investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for NTLA
Angioedema Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angioedema pipeline constitutes 20+ key companies continuously working towards developing 20+ Angioedema treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Angioedema Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
CRISPR Therapies Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, The …
(Albany, USA) DelveInsight's "CRISPR Therapies Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the CRISPR Therapies market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.
The CRISPR therapies landscape is witnessing rapid growth and is powered by cutting-edge research…
Long-Term Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) shou …
An investigation was announced on behalf of current long-term investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) concerning potential breaches of fiduciary duties by certain directors of Intellia Therapeutics, Inc.
Investors who are current long term investors in Intellia Therapeutics, Inc. (NASDAQ: NTLA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
CRISPR Therapies Pipeline: Revolutionizing Treatment with 25+ Innovators Driving …
The CRISPR therapies landscape is witnessing rapid growth and is powered by cutting-edge research and transformative innovations. Pioneering companies like Tango Therapeutics, KSQ Therapeutics, CRISPR Therapeutics, Emendo Biotherapeutics, and Beam Therapeutics are leading the charge-reshaping therapeutic approaches and unlocking new possibilities in genetic medicine. With their groundbreaking advancements, these leaders are paving the way for a future where CRISPR-based treatments offer renewed hope and lasting impact for patients worldwide.
DelveInsight's "CRISPR…
Hereditary Angioedema Pipeline: Over 20 Leading Companies Driving Innovation wit …
The Hereditary Angioedema market is rapidly advancing and is fueled by groundbreaking research and innovative therapies from companies such as BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, and BioMarin Pharmaceutical. These industry pioneers are transforming treatment strategies and redefining the future of Hereditary Angioedema, bringing new hope to patients worldwide.
DelveInsight's "Hereditary Angioedema Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the Hereditary Angioedema market. The report covers…
Investors who lost money with shares of Intellia Therapeutics, Inc. (NASDAQ: NTL …
An investor, who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA), filed a lawsuit over alleged violations of Federal Securities Laws by Intellia Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) have certain options and for certain investors are short and strict deadlines running. Deadline: April 14, 2025. NASDAQ: NTLA investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
